20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
- Pacira BioSciences Inc (NASDAQ:PCRX) announced topline results from its Phase 3 study of EXPAREL as a single-dose femoral nerve block in the adductor canal for postsurgical regional analgesia in patients undergoing total knee arthroplasty.
- EXPAREL achieved the study's primary endpoint demonstrating a statistically significant reduction in cumulative pain scores from 0 to 96 hours compared with bupivacaine HCl.
- EXPAREL also achieved a statistically significant reduction in postsurgical opioid consumption through 96 hours compared with bupivacaine HCl.
- EXPAREL was well tolerated with a safety profile consistent with bupivacaine HCl.
- Pacira plans to submit a supplemental marketing application to the FDA early next year seeking expansion of the EXPAREL label to include femoral nerve block in the adductor canal.
- The company plans to submit the full results from the Phase 3 study for presentation at future scientific conferences and publication in a peer-reviewed journal.
- Price Action: PCRX shares are up 0.35% at $51.42 on the last check Wednesday.
20-Year Pro Trader Reveals His "MoneyLine"
Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!